Alternative Biomarkers for Combined Biology
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yong-Hyun | - |
dc.contributor.author | Kirsop, Jennifer | - |
dc.contributor.author | Tang, Wai Hong Wilson | - |
dc.date.accessioned | 2021-09-03T07:49:43Z | - |
dc.date.available | 2021-09-03T07:49:43Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-04 | - |
dc.identifier.issn | 1551-7136 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/83969 | - |
dc.description.abstract | Chemotherapy-related cardiac dysfunction (CRCD) has challenged clinicians to hesitate in using cardiotoxic agents such as anthracycline and several protein kinase inhibitors. As early detection of CRCD and timely cessation of cardiotoxic agents became a strategy to avoid CRCD, cardiac troponin and natriuretic peptide are measured to monitor cardiotoxicity; however, there are inconsistencies in their predictability of CRCD. Alternative biomarkers have been researched extensively for potential use as more sensitive and accurate biomarkers. The mechanisms of CRCD and previous studies on traditional and novel biomarkers for CRCD are examined to enlighten future direction of investigation in this combined biology. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.subject | ANTHRACYCLINE-INDUCED CARDIOTOXICITY | - |
dc.subject | VENTRICULAR EJECTION FRACTION | - |
dc.subject | CARDIAC TROPONIN-I | - |
dc.subject | GROWTH-DIFFERENTIATION FACTOR-15 | - |
dc.subject | CONTAINING ADJUVANT CHEMOTHERAPY | - |
dc.subject | PLASMA MYELOPEROXIDASE LEVELS | - |
dc.subject | BRAIN NATRIURETIC PEPTIDE | - |
dc.subject | BREAST-CANCER PATIENTS | - |
dc.subject | MULTIPLE BIOMARKERS | - |
dc.subject | HEART-FAILURE | - |
dc.title | Alternative Biomarkers for Combined Biology | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Hyun | - |
dc.identifier.doi | 10.1016/j.hfc.2016.12.009 | - |
dc.identifier.scopusid | 2-s2.0-85014484670 | - |
dc.identifier.wosid | 000398763800011 | - |
dc.identifier.bibliographicCitation | HEART FAILURE CLINICS, v.13, no.2, pp.381 - + | - |
dc.relation.isPartOf | HEART FAILURE CLINICS | - |
dc.citation.title | HEART FAILURE CLINICS | - |
dc.citation.volume | 13 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 381 | - |
dc.citation.endPage | + | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | ANTHRACYCLINE-INDUCED CARDIOTOXICITY | - |
dc.subject.keywordPlus | VENTRICULAR EJECTION FRACTION | - |
dc.subject.keywordPlus | CARDIAC TROPONIN-I | - |
dc.subject.keywordPlus | GROWTH-DIFFERENTIATION FACTOR-15 | - |
dc.subject.keywordPlus | CONTAINING ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | PLASMA MYELOPEROXIDASE LEVELS | - |
dc.subject.keywordPlus | BRAIN NATRIURETIC PEPTIDE | - |
dc.subject.keywordPlus | BREAST-CANCER PATIENTS | - |
dc.subject.keywordPlus | MULTIPLE BIOMARKERS | - |
dc.subject.keywordPlus | HEART-FAILURE | - |
dc.subject.keywordAuthor | Chemotherapy-related cardiac dysfunction | - |
dc.subject.keywordAuthor | Heart failure | - |
dc.subject.keywordAuthor | Malignancy | - |
dc.subject.keywordAuthor | Biomarkers | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.